Johnson & Johnson Takes Position in Neumora Therapeutics, Inc. $NMRA

Johnson & Johnson purchased a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,849,445 shares of the company’s stock, valued at approximately $3,144,057,000. Neumora Therapeutics makes up about 0.4% of Johnson & Johnson’s holdings, making the stock its 12th biggest position.

Other large investors also recently modified their holdings of the company. Siren L.L.C. increased its holdings in Neumora Therapeutics by 35.1% during the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock worth $16,571,000 after acquiring an additional 2,209,039 shares during the period. Perceptive Advisors LLC bought a new position in Neumora Therapeutics in the 1st quarter valued at $9,953,000. Millennium Management LLC boosted its holdings in Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after purchasing an additional 1,608,266 shares during the period. Renaissance Technologies LLC boosted its holdings in Neumora Therapeutics by 24.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock valued at $2,588,000 after purchasing an additional 281,926 shares during the period. Finally, Ikarian Capital LLC grew its position in shares of Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after purchasing an additional 1,265,910 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $1.60 on Friday. Neumora Therapeutics, Inc. has a 52-week low of $0.83 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.09 and a current ratio of 5.09. The company has a market capitalization of $296.45 million, a P/E ratio of -1.30 and a beta of 2.75. The company has a fifty day moving average of $1.61 and a 200-day moving average of $2.12.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01. As a group, equities research analysts predict that Neumora Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NMRA has been the topic of several research analyst reports. Royal Bank Of Canada decreased their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Mizuho reduced their target price on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, June 18th. Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.57.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.